Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program.
Page 2

The organizers of the program hopes for the outcome of the project to have a substantial impact bioequivalence policy development for generic orally inhaled products.

Furthermore, the initiatives included under this funding opportunity announcement also intends to achieve the following objectives:

a) Develop a quality-by-design tool that could be utilized to improve the performance of orally inhaled drugs during the product development phase.

b) Determine accurate dose predictions.

c) Set clinical relevant aerodynamic particle size distribution specifications to ensure product quality, for these drug/device combination products.

To support these initiatives, the USFDA is ready to administer funds in the amount of $150,000.

The institutions and organizations who will be deemed eligible to submit an application under this program are the following:

a) Private and Public Non-profit entities

b) State and Local Governments

c) Indian Tribal Governments and Organizations

d) Faith-based Organizations

e) Community-based Organizations

f) Institutions of Higher Education

g) Private and Public Colleges and Universities

h) Independent School Districts

The Department of Health and Human Services, the mother agency funding the Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program, is the nation's leading agency for protecting the health of all Americans and providing fundamental human services to all.

Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program.
  Back to Page 1

About The Author Iola Bonggay is an editor of TopGovernmentGrants.com one the the most comprehensive Websites offering information on government grants and federal government programs. She also maintains Websites providing resources on environmental grants and grants for youth programs.

Additional Resources

category - Health Grants

Core Clinical Centers for the Cardiothoracic Surgical Trials Network Program
In keeping with this mission, the National Institutes of Health has partnered with the Canadian Institutes of Health Research (CIHR), the National Heart, Lung, and Blood Institute (NHLBI), and the Institute of Circulatory and Respiratory Health (ICRH) to establish the Core Clinical Centers for the Cardiothoracic Surgical Trials Network Program.

---

Scale-Up of Care and Support Services for Orphans and Vulnerable Children in Nigeria
The USAID office in Nigeria has recently established a program called Scale-Up of Care and Support Services for Orphans and Vulnerable Children wherein it intends to improve the health and well-being of orphans and vulnerable children in Nigeria by way of developing a sustainable, comprehensive and coordinated program that will potentially help these kids live a normal, and healthy life.

---

Mobile Health Tools to Promote Effective Patient Provider Communication to Underserved Populations
The National Institute of Nursing Research, in cooperation with the Office of Dietary Supplements has constituted the funding opportunity for Mobile Health tools aimed at the improvement of effective patient-provider communication, adherence to treatment and self-management of chronic diseases in underserved populations.

---

Leadership Group for a Clinical Research Network on Antibacterial Resistance Program
In line with this mission, the National Institutes of Health has collaborated with the National Institute of Allergy and Infectious Diseases (NIAID) in an attempt to establish the Leadership Group for a Clinical Research Network on Antibacterial Resistance Program.

---